You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 16, 2025

Anbison Lab Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ANBISON LAB

ANBISON LAB has four approved drugs.



Summary for Anbison Lab
US Patents:0
Tradenames:3
Ingredients:3
NDAs:4

Drugs and US Patents for Anbison Lab

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Anbison Lab BUPROPION HYDROCHLORIDE bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 207224-002 Jun 30, 2017 AB3 RX No No ⤷  Try for Free ⤷  Try for Free
Anbison Lab CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 212948-002 Sep 30, 2021 AB RX No No ⤷  Try for Free ⤷  Try for Free
Anbison Lab CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 212948-001 Sep 30, 2021 AB RX No No ⤷  Try for Free ⤷  Try for Free
Anbison Lab CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 212948-003 Sep 30, 2021 AB RX No No ⤷  Try for Free ⤷  Try for Free
Anbison Lab MONTELUKAST SODIUM montelukast sodium TABLET, CHEWABLE;ORAL 205695-002 Nov 5, 2015 AB RX No No ⤷  Try for Free ⤷  Try for Free
Anbison Lab MONTELUKAST SODIUM montelukast sodium TABLET, CHEWABLE;ORAL 205695-001 Nov 5, 2015 AB RX No No ⤷  Try for Free ⤷  Try for Free
Anbison Lab MONTELUKAST SODIUM montelukast sodium TABLET;ORAL 205683-001 Jan 12, 2016 AB RX No No ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 7 of 7 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Anbison Lab – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, companies must constantly adapt and innovate to maintain their competitive edge. Anbison Lab, a rising star in the field, has been making waves with its unique approach to drug development and market strategy. This comprehensive analysis delves into Anbison Lab's market position, strengths, and strategic insights, providing a detailed look at how this company is navigating the complex pharmaceutical landscape.

The Rise of Anbison Lab

Founded in 2007, Anbison Lab has quickly established itself as a formidable player in the pharmaceutical industry[1]. Initially operating as a Contract Research Organization (CRO), the company has since expanded its operations to become a full-fledged pharmaceutical manufacturer and innovator[2].

From CRO to Market Authorization Holder

Anbison Lab's journey from a CRO to a Market Authorization Holder (MAH) is a testament to its adaptability and foresight. In 2016, taking advantage of new legislation in China, Anbison became the first Chinese pharmaceutical R&D company without its own manufacturing facility to file its own product[2]. This strategic move positioned Anbison at the forefront of a changing regulatory landscape, demonstrating its ability to capitalize on industry shifts.

Anbison Lab's Market Position

Anbison Lab has carved out a unique position in the pharmaceutical market, focusing on high-end controlled-release dosage forms and complex finished dosage forms[1]. This specialization has allowed the company to differentiate itself from competitors and establish a strong foothold in both domestic and international markets.

Global Reach and Expansion

With a presence in China, the United States, and the United Kingdom, Anbison Lab has demonstrated its commitment to global expansion[2][9]. This international footprint not only diversifies the company's revenue streams but also provides access to a wider pool of talent and resources.

Anbison is dedicated to research, development (R&D) and production of high-end generic drugs which have its quality and efficacy in consistency with that of the original ones as well as improved new drug with clinical advantages; aimed at both domestic and oversea markets of pharmaceutical preparations[2].

Key Strengths of Anbison Lab

1. Innovative R&D Approach

Anbison Lab's core strength lies in its innovative approach to research and development. The company focuses on developing high-end generic drugs and improved new drugs with clinical advantages[2]. This strategy allows Anbison to balance the lower risk profile of generics with the potential high rewards of novel drug development.

2. Specialized Manufacturing Capabilities

With over 20,000 square meters of manufacturing facilities dedicated to multi-dosage form, modified release, and long-lasting injection production[2], Anbison Lab possesses the infrastructure necessary to produce complex pharmaceutical products at scale.

3. Strong Track Record of Regulatory Approvals

Anbison Lab has successfully developed and filed more than 60 generics in the U.S. and China markets, with over 30 receiving approval[2]. This track record demonstrates the company's ability to navigate complex regulatory environments and bring products to market efficiently.

4. Strategic Partnerships

Anbison Lab has built close cooperative relationships with leading domestic pharmaceutical companies[2]. These partnerships enable the company to leverage external manufacturing capabilities, enhancing its flexibility and scalability.

Anbison Lab's Strategic Insights

Focus on High-Value Markets

Anbison Lab's strategy of targeting high-end controlled-release dosage forms and complex finished dosage forms[1] allows it to operate in market segments with higher barriers to entry and potentially higher profit margins.

Balancing Generic and Innovative Drug Development

By maintaining a portfolio that includes both high-end generic drugs and innovative preparations[1], Anbison Lab mitigates risk while still pursuing potentially groundbreaking therapies.

Leveraging Regulatory Changes

Anbison Lab's quick adaptation to China's Market Authorization Holder system[2] showcases its ability to capitalize on regulatory changes, a crucial skill in the highly regulated pharmaceutical industry.

Commitment to Quality and Efficiency

Anbison Lab's focus on quality assurance and production efficiency[2] aligns with global pharmaceutical trends and regulatory requirements, positioning the company as a reliable and competitive player in the market.

Competitive Landscape Analysis

Major Competitors

While specific competitors are not mentioned in the provided search results, it's important to note that Anbison Lab operates in a highly competitive industry. Major pharmaceutical companies and other innovative biotech firms likely constitute its main competition.

Industry Trends Impacting Anbison Lab

1. Increasing Focus on Rare Diseases and Personalized Medicine

Companies like Ascendis Pharma are focusing on rare diseases and personalized medicine[4]. This trend could present both opportunities and challenges for Anbison Lab, depending on its current pipeline and research focus.

2. Emphasis on Innovative Drug Delivery Technologies

AstraZeneca's success with its 5R framework (right target, right patient, right tissue, right safety, right commercial potential)[3] highlights the industry's move towards more targeted and efficient drug development processes. Anbison Lab's focus on controlled-release dosage forms aligns well with this trend.

3. Growing Importance of Strategic Partnerships

As seen with Ascendis Pharma[4], strategic partnerships are becoming increasingly crucial in the pharmaceutical industry. Anbison Lab's existing partnerships with domestic pharmaceutical companies position it well in this regard.

Anbison Lab's Future Outlook

Opportunities for Growth

  1. Expansion into New Therapeutic Areas: Anbison Lab could consider expanding its research into additional high-value therapeutic areas, following the trend set by companies like Ascendis Pharma[4].

  2. Further International Expansion: With its existing presence in China, the US, and the UK, Anbison Lab is well-positioned to continue its global expansion, potentially entering new markets in Europe or emerging economies.

  3. Investment in Cutting-Edge Technologies: As demonstrated by AstraZeneca's use of CRISPR/Cas9 and advanced drug discovery robots[3], investing in state-of-the-art technologies could further enhance Anbison Lab's R&D capabilities.

Potential Challenges

  1. Regulatory Hurdles: As Anbison Lab expands globally, navigating diverse regulatory environments will be crucial.

  2. Intense Competition: The pharmaceutical industry is highly competitive, with both established players and innovative startups vying for market share.

  3. Balancing Innovation and Cost-Effectiveness: As healthcare systems worldwide grapple with rising costs, Anbison Lab will need to continue delivering innovative products while maintaining cost-effectiveness.

Key Takeaways

  • Anbison Lab has successfully transitioned from a CRO to a full-fledged pharmaceutical company with a global presence.
  • The company's focus on high-end controlled-release dosage forms and complex finished dosage forms sets it apart in the market.
  • Anbison Lab's strong track record of regulatory approvals and strategic partnerships position it well for future growth.
  • The company's ability to adapt to regulatory changes and industry trends will be crucial for its continued success.
  • Balancing generic and innovative drug development provides Anbison Lab with a diversified portfolio and risk mitigation strategy.
  • Future opportunities lie in expanding therapeutic areas, further international expansion, and investment in cutting-edge technologies.

FAQs

  1. Q: What is Anbison Lab's core business focus? A: Anbison Lab focuses on the research, development, and production of high-end controlled-release dosage forms and complex finished dosage forms.

  2. Q: How has Anbison Lab expanded internationally? A: Anbison Lab has established a presence in China, the United States, and the United Kingdom, demonstrating its commitment to global expansion.

  3. Q: What sets Anbison Lab apart from its competitors? A: Anbison Lab's specialization in high-end generic drugs and improved new drugs with clinical advantages, along with its strong manufacturing capabilities and regulatory track record, differentiate it in the market.

  4. Q: How does Anbison Lab balance risk in its product portfolio? A: Anbison Lab maintains a portfolio that includes both high-end generic drugs and innovative preparations, mitigating risk while still pursuing potentially groundbreaking therapies.

  5. Q: What are some key challenges Anbison Lab may face in the future? A: Potential challenges include navigating diverse regulatory environments as it expands globally, intense competition in the pharmaceutical industry, and balancing innovation with cost-effectiveness.

Sources cited:

  1. https://www.anbison.com/en
  2. https://www.anbison.com/en/aboutus-list.html
  3. https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/transforming-astrazenecas-rd-productivity.html
  4. https://canvasbusinessmodel.com/blogs/competitors/ascendis-pharma-competitive-landscape
  5. https://find-and-update.company-information.service.gov.uk/company/12572760

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.